Quality of Life, Anxiety and Depressive Symptoms in North Sea–Progressive Myoclonus Epilepsy: A Comparative Analysis With Other Hyperkinetic Movement Disorders

Objectives: North Sea–Progressive Myoclonus Epilepsy (NS‐PME) is a rare, childhood‐onset disorder primarily characterized by movement disorders including progressive myoclonus and ataxia; subsequently accompanied by varying degrees of epilepsy. While motor symptoms are clearly defined, quality of life (QoL) has never been investigated in NS‐PME. Additionally, nonmotor symptoms (NMS) including anxiety, depression, and cognitive problems are known to impact QoL and are increasingly being reported in other movement disorders. Hence, we examined the presence of anxiety and depression symptoms and the degree of QoL in NS‐PME. Materials and Methods: Data were collected from multiple cross‐sectional, survey‐based studies conducted between 2014 and 2020 at the University Medical Center Groningen (UMCG), the Netherlands. First, data on QoL, anxiety, and depression symptoms were collected from 11 persons with NS‐PME. Second, to compare outcomes in NS‐PME with controls ( n = 21) and other hyperkinetic movement disorders (HMDs; n = 146), data from previously conducted studies in the UMCG were reused. The surveys used include the SF‐36/RAND‐36, the Beck Anxiety Inventory (BAI), and the Beck Depression Inventory (BDI). Results: Symptoms of anxiety and depression were not present in the majority of persons with NS‐PME. Compared to QoL scores of controls and other HMDs, persons with NS‐PME scored significantly worse on physical functioning domains and, although nonsignificant, rendered the highest scores on emotional functioning domains. Conclusion: Firstly, we did not find indications for significantly increased anxiety or depression symptoms in NS‐PME. Secondly, our findings on QoL in NS‐PME reveal the following: (1) a floor effect of the SF‐36 questionnaire and (2) suggest a disability paradox in NS‐PME, in which persons with NS‐PME reported good emotional well‐being, despite physical challenges. To explore the presence of a disability paradox further and generate more suitable QoL measures for movement disorders such as NS‐PME, future studies should elaborate on personal perspectives, including the exploration of coping mechanisms.

Authors

Institutions

Publication Details

Journal
Acta Neurologica Scandinavica
Published
2025-01-01
DOI
https://doi.org/10.1155/ane/3302536
Primary Topic
Glycogen Storage Diseases and Myoclonus
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quality of Life, Anxiety and Depressive Symptoms in North Sea–Progressive Myoclonus Epilepsy: A Comparative Analysis With Other Hyperkinetic Movement Disorders

Sjoukje S. Polet, Elze R. Timmers, Talitha Bent, Tom J. de Koning et al.
1 links
Acta Neurologica Scandinavica
Glycogen Storage Diseases and Myoclonus
article

Quality of Life, Anxiety and Depressive Symptoms in North Sea–Progressive Myoclonus Epilepsy: A Comparative Analysis With Other Hyperkinetic Movement Disorders

Sjoukje S. Polet, Elze R. Timmers, Talitha Bent, Tom J. de Koning, Marina A.J. Tijssen
article en

Abstract

Objectives: North Sea–Progressive Myoclonus Epilepsy (NS‐PME) is a rare, childhood‐onset disorder primarily characterized by movement disorders including progressive myoclonus and ataxia; subsequently accompanied by varying degrees of epilepsy. While motor symptoms are clearly defined, quality of life (QoL) has never been investigated in NS‐PME. Additionally, nonmotor symptoms (NMS) including anxiety, depression, and cognitive problems are known to impact QoL and are increasingly being reported in other movement disorders. Hence, we examined the presence of anxiety and depression symptoms and the degree of QoL in NS‐PME. Materials and Methods: Data were collected from multiple cross‐sectional, survey‐based studies conducted between 2014 and 2020 at the University Medical Center Groningen (UMCG), the Netherlands. First, data on QoL, anxiety, and depression symptoms were collected from 11 persons with NS‐PME. Second, to compare outcomes in NS‐PME with controls ( n = 21) and other hyperkinetic movement disorders (HMDs; n = 146), data from previously conducted studies in the UMCG were reused. The surveys used include the SF‐36/RAND‐36, the Beck Anxiety Inventory (BAI), and the Beck Depression Inventory (BDI). Results: Symptoms of anxiety and depression were not present in the majority of persons with NS‐PME. Compared to QoL scores of controls and other HMDs, persons with NS‐PME scored significantly worse on physical functioning domains and, although nonsignificant, rendered the highest scores on emotional functioning domains. Conclusion: Firstly, we did not find indications for significantly increased anxiety or depression symptoms in NS‐PME. Secondly, our findings on QoL in NS‐PME reveal the following: (1) a floor effect of the SF‐36 questionnaire and (2) suggest a disability paradox in NS‐PME, in which persons with NS‐PME reported good emotional well‐being, despite physical challenges. To explore the presence of a disability paradox further and generate more suitable QoL measures for movement disorders such as NS‐PME, future studies should elaborate on personal perspectives, including the exploration of coping mechanisms.

Acta Neurologica ScandinavicaVol. 2025(1)
University Medical Center Groningen (NL), Lund University (SE)
Openalex Percentile: Top 92%
Glycogen Storage Diseases and Myoclonus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.